Feature | April 02, 2009

McKesson Releases Molecular Diagnostics Criteria Upgrade

April 2, 2009 - McKesson’s releases its 2009 InterQual Criteria and CareEnhance Review Manager 8.0 software features industry-leading innovations including molecular and genetic diagnostics criteria.

The new criteria, combined with the option for clients to access it via McKesson’s recently launched auto authorization capability, is designed to increase the value of the content for users while helping improve quality of care for patients.

“As we bring the latest versions of our criteria and software to market, we are focused on driving efficiencies for payors and providers while expanding into new content areas,” said Tammie Phillips, vice president of InterQual for McKesson Health Solutions. “Even as we address major industry issues with our new auto authorization functionality and molecular diagnostics content, we continue to enhance and add value to the existing elements of our solution suite that have made it the gold standard in evidence-based clinical decision support.”

McKesson’s auto authorization is a hosted, Web-based offering that leverages McKesson’s new Advanced Diagnostics Management solution. The offering automates the entire authorization process, from the initial request all the way through final authorization. McKesson’s auto authorization capability can incorporate InterQual Molecular Diagnostics Criteria and select Imaging Criteria—and soon selected Procedures Criteria—so that medical appropriateness is determined automatically for most requests. The content plus technology drive reduced administrative costs, better payor-provider relations and support optimal care.

The new InterQual Molecular Diagnostics Criteria is an important innovation included in this release. McKesson provides a comprehensive set of criteria to support decision-making for molecular diagnostic tests.

Molecular Diagnostics Criteria is updated quarterly so it is always current. To help healthcare organizations determine test appropriateness based on clinical evidence, InterQual Molecular Diagnostics Criteria covers over 225 tests that comprise approximately 85 percent of the costs in this growing area. A new question and answer format leads to service recommendations that include alternative and concurrent tests, allowing users to easily conduct reviews and act on information. In addition, pop-up notes and clinical evidence summaries drive evidence-based medicine to the point of decision-making with more efficiency. The content is available in CareEnhance Review Manager software as well as McKesson’s Advanced Diagnostics Management solution auto authorization capability.

For more information: www.mckesson.com

Related Content

Sponsored Content | Videos | Business | July 28, 2017
Angelic McDonald, MSRS, CRA, FAHRA, regional director of imaging, Baylor Scott & White Health and the president-e
CareSelect Declared Fully Qualified Clinical Decision Support Mechanism by CMS
News | Clinical Decision Support | July 18, 2017
National Decision Support Company announced the full qualification of its CareSelect Platform as a Qualified Clinical...
CMS Proposes Delaying Clinical Decision Support Documentation to 2019
News | Clinical Decision Support | July 14, 2017 | Jeff Zagoudis, Associate Editor
In a series of proposed rule changes to the Medicare Physician Fee Schedule (MPFS) released July 13, the Centers for...
News | Artificial Intelligence | July 07, 2017
July 7, 2017 — Zebra Medical Vision and Telerad Tech, the technology arm of Teleradiology Solutions (TRS), announced
ACR Launches Updated LI-RADS for Liver Imaging
News | Clinical Decision Support | July 06, 2017
July 6, 2017 — Radiologists can improve their consistency of interpreting and reporting...
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Fujitsu Develops AI-Based Technology to Retrieve Similar Disease Cases in CT Inspections

Newly developed technology to retrieve similar cases. Image courtesy of Fujitsu.

News | Artificial Intelligence | June 26, 2017
Fujitsu Laboratories Ltd. announced development of a technology to retrieve similar disease cases from a computed...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
Overlay Init